- Miragen has had years of disappointing share price performance with a cumulative loss of more than 90%.
- This is a reflection of the poor results in the two drug candidates that until recently composed its pipeline: Cobomarsen and Remlarsen.
- On October 28, the company wanted to make a radical change in its strategy by acquiring Viridian Therapeutics, and thus obtain the rights to VRDN-001.
- With a market cap of just $78 million, the risk/reward ratio here makes it worth entering with a small speculative position.
For further details see:
Miragen: Viridian Therapeutics Acquisition Offers Good Speculative Entry Opportunity